← Back to Directory

Estradiol

E2, 17β-estradiol, Oestradiol

Visual ViewRaw Data

Meta Information

ID:estradiol
Name:Estradiol
Schema Version:1.5

Alternate Names

  • E2
  • 17β-estradiol
  • Oestradiol

Active Compound

estradiol

Intervention Type

therapeutic_agent

Delivery

Route:
multiple
Scope:
  • systemic

Regulatory Status

  • us:rx_drug
  • eu:rx_drug

Indication

Focus:
healthspan
Description:
Used in post-menopausal women to restore physiological hormone levels, mitigating age-related decline in bone density, cardiovascular health, and cognitive function.

Typical Protocol

  • Oral: 1-2 mg daily.
  • Transdermal Patch: 0.025 to 0.1 mg/day applied once or twice weekly.
  • Topical Gel: 0.5 to 1.0 mg applied daily.
  • Must be co-administered with progesterone in women with an intact uterus.

Expected Cost Mean

Low Cost:
30
High Cost:
150
Cost Type:
monthly
Description:
Cost for generic transdermal patches or gels; often covered by insurance for menopause.

Summary

Estradiol is the primary female sex hormone. For healthspan, systemic hormone replacement therapy (HRT) in post-menopausal women aims to restore youthful physiological levels, which has been shown to preserve bone mineral density, improve cardiovascular markers, and support cognitive function. Its use is primarily focused on mitigating the broad systemic effects of menopause-related hormonal decline.

Purpose

Restores youthful hormone levels to mitigate menopause-related aging.

Card Summary

A primary female sex hormone used in post-menopausal women to preserve bone density, cardiovascular health, and cognitive function by restoring physiological levels.

Drug Class

estrogens

Drugs In Class

Empty Array

Impact

Score:
8.2
Justification:
Foundational for post-menopausal women, mitigating major drivers of age-related disease.

Evidence

Grade:
A
Score:
9
Justification:
Extensive human RCTs and meta-analyses on menopause-related health outcomes.

Safety

Score:
5.8
Justification:
Requires medical supervision due to risks of VTE and certain cancers.

Flags

  • Unopposed estrogen (without progesterone) increases risk of endometrial cancer in women with a uterus.
  • Increased risk of venous thromboembolism (VTE) and stroke, particularly with oral formulations.
  • May increase risk of certain breast cancers, a topic of ongoing research and debate.
  • Contraindicated in individuals with a history of breast cancer, VTE, or certain liver diseases.
  • Transdermal routes (patches, gels) avoid first-pass liver metabolism and carry a lower risk of blood clots compared to oral estradiol.

Verdict

A foundational healthspan intervention for post-menopausal women under medical supervision.

Qualifier

systemic, focused on healthspan

Created

2026-04-29T19:48:44.072639Z

Ai Model

Gemini 2.5 Pro (High)